Non-HDL Cholesterol: Normal Range, Results & What They Mean
Everything you need to know about Non-HDL Cholesterol: Normal Range, Results & What They Mean test results, including normal ranges and what abnormal levels might mean.
Reference Range
Unit: mg/dLReference Range
Reference ranges vary by laboratory. Always consult your healthcare provider for interpretation of your specific results.
What is Non-HDL Cholesterol?
Non-HDL cholesterol is like a comprehensive count of all the "bad" cholesterol particles in your blood. While LDL cholesterol gets most of the attention, non-HDL captures ALL atherogenic particles: LDL, VLDL, IDL, remnant lipoproteins, and Lp(a). It's calculated simply by subtracting HDL (the "good" cholesterol) from total cholesterol.
Think of it this way: total cholesterol is all the cholesterol in your blood. HDL is protective. Everything else has the potential to contribute to plaque buildup. Non-HDL is everything else—the sum of all particles that can deposit cholesterol in artery walls.
Why does this matter? In people with high triglycerides, LDL-C may underestimate risk because standard calculation formulas (Friedewald equation) become inaccurate, and because triglyceride-rich remnants are themselves atherogenic. Non-HDL doesn't require calculation (it's directly measured) and captures all the particles that matter.
The Triglyceride Connection
When triglycerides are above 200 mg/dL, non-HDL is a better predictor of cardiovascular risk than LDL alone. Triglyceride-rich remnants (VLDL, IDL) are themselves atherogenic—they contribute to plaque formation just like LDL. Non-HDL captures these particles that LDL-C misses.
Understanding Your Results
Non-HDL is measured in milligrams per deciliter (mg/dL). Targets depend on your overall cardiovascular risk:
Understanding Your Results (mg/dL)
Minimal atherogenic particle burden
Low risk—healthy level
Moderately increased risk
High risk—intervention needed
Very high risk—aggressive management
Severe risk—urgent intervention
Why Non-HDL Levels Change
Non-HDL elevation reflects an excess of atherogenic lipoproteins from various causes:
Causes of Elevated Non-HDL Cholesterol
| Factor | Effect | What to Do |
|---|---|---|
| Metabolic syndrome and insulin resistance | Increases | Insulin resistance causes the liver to overproduce VLDL, elevating both triglycerides and non-HDL. This pattern (high triglycerides, low HDL, high non-HDL) is a hallmark of metabolic syndrome. Treatment: lifestyle changes (weight loss 5-10%, regular exercise, reduce refined carbs and sugars), possibly metformin. Address all metabolic syndrome components. |
| High saturated fat intake | Increases | Dietary saturated fat raises LDL cholesterol, which directly increases non-HDL. Common sources: red meat, full-fat dairy, butter, coconut oil, palm oil. Treatment: reduce saturated fat intake (<7% of calories), replace with unsaturated fats (olive oil, avocado, nuts, fatty fish). Portfolio diet (plant sterols, nuts, soluble fiber) can lower non-HDL by 20-30%. |
| Familial hypercholesterolemia (genetic) | Increases | Inherited condition causing LDL receptor deficiency, leading to marked LDL and non-HDL elevation. Causes premature cardiovascular disease. Treatment: high-intensity statins, ezetimibe, possibly PCSK9 inhibitors. Early diagnosis and aggressive treatment essential. Cascade screening of family members recommended. |
| Hypothyroidism | Increases | Low thyroid function slows LDL clearance, raising LDL and non-HDL. Treatment: thyroid hormone replacement (levothyroxine). Non-HDL typically normalizes with adequate thyroid treatment. Screen TSH when non-HDL is elevated without obvious cause. Thyroid optimization may resolve lipid abnormalities. |
| Kidney disease (nephrotic syndrome) | Increases | Kidneys normally filter and clear lipoproteins. Nephrotic syndrome causes massive protein loss in urine, triggering liver overproduction of lipoproteins including LDL and VLDL. Non-HDL rises significantly. Treatment: address underlying kidney disease, statins for lipid lowering, possibly albumin replacement. Nephrology management essential. |
| High refined carbohydrate and sugar intake | Increases | Excess sugars (especially fructose) are converted to fat in the liver, increasing VLDL production. This elevates both triglycerides and non-HDL. High-fructose corn syrup, sugary beverages, and refined carbs are major contributors. Treatment: reduce sugar intake, eliminate sugary drinks, choose whole grains over refined, increase fiber. |
Always tell your doctor about medications, supplements, and recent health events before testing.
LDL-C vs. Non-HDL: When They Disagree
Sometimes LDL and non-HDL tell different stories, especially with high triglycerides:
When Non-HDL Patterns Guide Management
Specific non-HDL patterns combined with other lipids reveal different risk profiles:
Non-HDL Patterns and Their Meaning
Non-HDL must be interpreted with triglycerides, HDL, LDL, and overall cardiovascular risk.
Non-HDL >130 with triglycerides >200
Atherogenic dyslipidemia pattern. High triglycerides mean triglyceride-rich remnants (VLDL, IDL) contribute to non-HDL elevation. These remnants are themselves atherogenic. Cardiovascular risk is higher than LDL alone suggests. Treatment focus: lower triglycerides (weight loss, exercise, reduce sugars/refined carbs, omega-3 fats, possibly fibrates) along with LDL-lowering.
Non-HDL >130 with normal triglycerides and low HDL
Isolated high LDL pattern. Non-HDL elevation primarily from LDL. Low HDL is an independent risk factor. Treatment: intensive LDL lowering (statins, lifestyle), raise HDL (exercise, smoking cessation, weight loss). This pattern has high cardiovascular risk that responds well to statin therapy.
Non-HDL <100 with normal HDL and triglycerides
Optimal lipid pattern. Low atherogenic burden, good protective HDL. Continue heart-healthy lifestyle: balanced diet low in saturated fat, regular exercise, maintain healthy weight, don't smoke. This is the target pattern for cardiovascular risk reduction.
Non-HDL normal but high ApoB
Discordance pattern. ApoB counts atherogenic particles directly and may be elevated when non-HDL appears normal. This occurs with small, dense LDL particles (more atherogenic per particle). ApoB may reveal hidden risk. Treatment depends on overall risk assessment—consider more aggressive lipid lowering if other risk factors present.
Your Action Plan Based on Results
If your non-HDL is optimal (＜100 mg/dL):
- Excellent lipid profile
- Minimal atherogenic burden
- Continue heart-healthy lifestyle:
- Mediterranean-style diet
- Regular physical activity
- Maintain healthy weight
- Don't smoke
- Limit saturated fats
- Choose whole foods over processed
If your non-HDL is borderline high (130-159 mg/dL):
- Moderately increased cardiovascular risk
- Lifestyle intervention recommended:
- Reduce saturated fat (＜7% of calories)
- Eliminate trans fats
- Increase soluble fiber (oats, beans, fruits)
- Add plant sterols/stanols
- Moderate alcohol intake
- Achieve and maintain healthy weight
- Exercise 150 minutes/week moderate intensity
- Consider portfolio diet (nuts, soy, plant sterols, soluble fiber)
- Repeat lipid panel in 3-6 months
- Consider statin if other risk factors present
If your non-HDL is high (160-189 mg/dL):
- High cardiovascular risk
- Medical evaluation recommended
- Comprehensive risk assessment:
- Family history of premature cardiovascular disease
- Blood pressure
- Blood sugar (diabetes screening)
- Smoking status
- Other risk factors
- Treatment plan:
- Intensive lifestyle changes (as above)
- Statin therapy often indicated
- Possibly ezetimibe if statin alone insufficient
- Treat other risk factors (hypertension, diabetes)
- Repeat lipids in 6-8 weeks after starting treatment
If your non-HDL is very high (＞190 mg/dL):
- Very high cardiovascular risk
- Possible familial hypercholesterolemia
- Specialist consultation recommended (lipid specialist)
- Aggressive management:
- High-intensity statin therapy
- Often combination therapy (statin + ezetimibe)
- Possibly PCSK9 inhibitor if not at goal
- Screen family members (cascade screening)
- Consider other causes (hypothyroidism, kidney disease)
- Frequent monitoring until at goal
- Lifelong treatment typically required
If you have diabetes or established cardiovascular disease:
- Non-HDL target is lower: ＜80-100 mg/dL
- High-intensity statin typically recommended
- Risk is 2-4x higher without treatment
- Aggressive risk factor modification essential
The Non-HDL Advantage
Non-HDL is a better predictor of cardiovascular risk than LDL alone, especially when triglycerides are elevated. Unlike LDL calculation (which becomes inaccurate when TG ＞400), non-HDL is a direct measurement that's always accurate. Major guidelines now recommend non-HDL as a secondary target after LDL. Some experts argue non-HDL should be the primary target—it captures all atherogenic particles and doesn't require calculation."
Common Questions
Track Your Non-HDL Cholesterol Results
Monitor your levels over time, identify trends, and share your history with your doctor.